Clinical Trials Directory

Trials / Unknown

UnknownNCT05716750

Serum Prolidase Activity and the Role of Leptin in Osteomalacia

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
38 (estimated)
Sponsor
TUĞBA ŞAHBAZ · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Evaluation of the change of serum Prolidase and Leptin values in the diagnosis and follow-up of osteomalacia and its clinical usability

Detailed description

Osteomalacia describes a bone disorder in adults that is usually caused by long-term vitamin D deficiency. Osteomalacia, a metabolic bone disease characterized by impaired mineralization of the bone matrix.Not a single laboratory finding is specific to osteomalacia.The relationship between collagen and prolidase activity has been observed during fibrotic processes, where an increase in prolidase activity is accompanied by an increase in tissue collagen deposition. It has also been suggested that serum activity is increased in metabolic bone diseases.Leptin is a 16 kDa peptide hormone. It is a member of the long chain helical cytokine family, which is mainly produced by fat cells and proportional to the size of the stored fat. Leptin affects bone remodeling by reducing the activity of osteoclasts and thus participates in the pathogenesis of osteoporosis. In the light of these studies, the investigators planned our study according to the clinical significance of serum prolidase activity in osteomalacia and the place of leptin in osteomalacia.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTVitamin D50,000 IU vit D treatment for 8 weeks

Timeline

Start date
2023-02-15
Primary completion
2023-04-30
Completion
2023-06-30
First posted
2023-02-08
Last updated
2023-02-14

Source: ClinicalTrials.gov record NCT05716750. Inclusion in this directory is not an endorsement.

Serum Prolidase Activity and the Role of Leptin in Osteomalacia (NCT05716750) · Clinical Trials Directory